BTS Research News
What's new at BTS
BTS Research Completes Corrections of FDA 483 Observations
BTS Research Completes Corrections of FDA 483 Observations From the desk of the President & CEO On July 8, 2022, U.S. Food and Drug Administration (FDA) Investigator concluded an inspection of the BTS Research facilities located in San Diego, CA and issued Inspectional Observations on the form FDA-483 that triggered a Warning Letter issued on…
COVID-19 Response
BTS Research is taking in animals for temporary housing from local vivariums BTS provides services in the following research animals: Rodents. Rabbits. Guinea pigs. Dogs NHP’s. Contact us for more details.
BTS Research Passes an FDA Bioresearch Monitoring Program Inspection for GLP Rat and Dog Toxicity Studies
BTS Research is pleased to share with its clients the results of the FDA audit which was concluded on December 4th, 2019. Following a 14-day onsite inspection, the FDA concluded their inspection of a 2-week GLP Rat Intravenous study and a 26-Week GLP Oral dog study for two of BTS’ clients. The FDA affirmed that…
BTS Research Passed USDA Inspection 2018
BTS Research is finishing 2018 on a high note BTS Research is pleased to report this year’s USDA inspection has been completed with 0 findings. Since BTS incubation in 2001, aside from minor recommendations from USDA that were addressed immediately, BTS enjoys a clean track record with all regulating agencies with no violations. Site 002…
Advanced NHP Research Capabilities: Molecular Imaging
BTS Research has partnered with BioLaurus Inc. , an advanced molecular imaging group to bring new research capabilities to our pharma research clients. The gold standard for pre-clinical research has long been the non human primate (NHP) but access to NHP and advanced research capabilities has become ever more challenging. To meet this challenge there…
BTS Research’s, Sam Abunadi President & CEO, urges the FDA to require “Clinical Trials” for Cannabis dose determination as a scheduled substance with not yet classified strands
With many cities and states now approving cannabis products, and without a doctor note, the American population at large is being invited to be a part of an uncontrolled drug influence clinical trial without a sufficiently regulated method to question the right dose determination hence consumers and non-consumers are subjected to possible danger. Now that…
BTS Research Appoints Mark Crane as Vice President, Business Development
SAN DIEGO–(BUSINESS WIRE)–BTS Research, a preclinical services Contract Research Organization, is delighted to announce the addition of Mark T. Crane as Vice President of Business Development. Mark will be taking on the Company’s Marketing, Sales, and Business Development efforts pushing BTS’s business growth model and fostering positive relationships with new and current clients. Particularly, Mark will be…
Pharma Companies in San Diego
BTS Research is not only one of the leading CRO pharma companies in San Diego, but also a front runner in global research. BTS Research offers its clients that are looking to hire research pharmaceutical companies in Southern California exceptional services in pharmaceutical/bio pharmaceutical, biotech, academic research, medical device development, and other related industries. BTS Research,…
Preclinical CRO
Looking for a preclinical CRO to aid in your research goals? Are you one of the many pharmaceutical companies in San Diego seeking support? California is a host for pharmaceutical companies who share a common challenge of needing to develop proper discovery animal model to help them with their proof of concept and their IND…
BTS Research Passed USDA Inspection
BTS Research is finishing the year on a high note BTS Research is pleased to report their USDA inspection has been completed with 0 findings. Since BTS incubation in 2001, aside from minor recommendations from USDA that were addressed immediately, BTS enjoys a clean track record with all regulating agencies with no violations. See attached…